Vera Therapeutics Grants Inducement Stock Awards to New Employees

Vera Therapeutics granted stock options and RSUs to ten new employees as part of its 2024 Inducement Plan.

Quiver AI Summary

Vera Therapeutics, Inc. announced the granting of inducement awards to ten new employees on June 2, 2026, consisting of non-qualified stock options for 28,800 shares and restricted stock units (RSUs) for 14,150 shares, as part of their 2024 Inducement Plan. The awards were approved by the Compensation Committee in compliance with Nasdaq rules, with stock options priced at $31.26 per share, based on that day's closing price. Both the stock options and RSUs will vest over four years, contingent on the employees' continued service. Vera Therapeutics focuses on developing treatments for immunological diseases, with their lead candidate, atacicept, targeting autoimmune conditions like IgAN and lupus nephritis. Additionally, the company is exploring other treatment options and holds licensing rights for new therapies in development.

Potential Positives

Vera Therapeutics has demonstrated its commitment to attracting talent by granting inducement awards of stock options and restricted stock units to ten new employees, which can enhance team capabilities and drive innovation.
The stock options have an exercise price equivalent to the company's current trading price, aligning employee interests with shareholder value and potentially increasing motivation among new hires.
This strategic move to expand the workforce through equity awards signals confidence in future growth and stability, contributing to investor and market perception positively.
Vera Therapeutics is advancing its mission to develop treatments for serious immunological diseases, indicating a strong focus on addressing significant healthcare needs, which may enhance the company's reputation in the biotech industry.

Potential Negatives

The issuance of stock options and RSUs to new employees may indicate that the company is relying heavily on incentivizing new talent, which could reflect challenges in attracting employees without such inducements.
The press release highlights a reliance on Nasdaq Listing Rule 5635(c)(4) for granting inducement awards, which may suggest that the company is facing difficulties in filling positions at standard compensation levels.
The specific mention of stock option grants at a fixed price could raise concerns among investors regarding the company's future stock performance and overall market confidence.

FAQ

What were the recent stock option awards by Vera Therapeutics?

Vera Therapeutics granted stock options for 28,800 shares and RSUs for 14,150 shares to ten new employees.

What is the exercise price of the stock options granted?

The exercise price for each stock option is $31.26, matching the closing price on June 2, 2026.

How will the stock options and RSUs vest?

Stock options vest over four years, while RSUs vest 25% annually based on the employee's start date.

Who received the inducement awards at Vera Therapeutics?

The inducement awards were granted to ten new employees as part of the 2024 Inducement Plan.

What is Vera Therapeutics focused on developing?

Vera Therapeutics develops treatments for serious immunological diseases, with a focus on targeting the source of diseases.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$VERA Insider Trading Activity

$VERA insiders have traded $VERA stock on the open market 15 times in the past 6 months. Of those trades, 1 have been purchases and 14 have been sales.

Here’s a breakdown of recent trading of $VERA stock by insiders over the last 6 months:

MARSHALL FORDYCE (PRESIDENT AND CEO) has made 0 purchases and 6 sales selling 58,376 shares for an estimated $2,401,375.
WILLIAM D. TURNER (Chief Regulatory Officer) has made 0 purchases and 3 sales selling 22,187 shares for an estimated $1,045,638.
PATRICK G ENRIGHT purchased 5,882 shares for an estimated $249,985
SEAN GRANT (CHIEF FINANCIAL OFFICER) sold 4,949 shares for an estimated $207,778
JOSEPH R YOUNG (SVP, FINANCE, CHIEF ACCT OFFCR) sold 3,117 shares for an estimated $130,863
DAVID LEE JOHNSON (Chief Operating Officer) sold 2,579 shares for an estimated $108,276
ROBERT BRENNER (Chief Medical Officer) sold 2,151 shares for an estimated $90,307
LAURENCE MATTHEW SKELTON (Chief Commercial Officer) sold 1,582 shares for an estimated $66,418

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$VERA Hedge Fund Activity

We have seen 142 institutional investors add shares of $VERA stock to their portfolio, and 93 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

TANG CAPITAL MANAGEMENT LLC removed 1,350,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $68,364,000
HOLOCENE ADVISORS, LP removed 1,307,393 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $50,864,124
DEEP TRACK CAPITAL, LP added 1,284,932 shares (+45.5%) to their portfolio in Q1 2026, for an estimated $49,990,279
EVERSEPT PARTNERS, LP removed 899,018 shares (-29.3%) from their portfolio in Q1 2026, for an estimated $34,976,295
PRICE T ROWE ASSOCIATES INC /MD/ removed 887,946 shares (-16.3%) from their portfolio in Q1 2026, for an estimated $34,545,539
VESTAL POINT CAPITAL, LP added 818,159 shares (+148.8%) to their portfolio in Q1 2026, for an estimated $31,830,475
TRI LOCUM PARTNERS LP removed 805,689 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $31,345,330

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$VERA Analyst Ratings

Wall Street analysts have issued reports on $VERA in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

B of A Securities issued a "Buy" rating on 12/19/2025
Goldman Sachs issued a "Buy" rating on 12/19/2025
JP Morgan issued a "Overweight" rating on 12/19/2025

To track analyst ratings and price targets for $VERA, check out Quiver Quantitative's $VERA forecast page.

$VERA Price Targets

Multiple analysts have issued price targets for $VERA recently. We have seen 7 analysts offer price targets for $VERA in the last 6 months, with a median target of $91.0.

Here are some recent targets:

Gavin Clark-Gartner from Evercore ISI Group set a target price of $91.0 on 05/15/2026
Andy Chen from Wolfe Research set a target price of $88.0 on 03/11/2026
Arthur He from HC Wainwright & Co. set a target price of $110.0 on 03/02/2026
Dina Ramadane from B of A Securities set a target price of $66.0 on 12/19/2025
Paul Choi from Goldman Sachs set a target price of $95.0 on 12/19/2025
Anupam Rama from JP Morgan set a target price of $96.0 on 12/19/2025
Laura Chico from Wedbush set a target price of $33.0 on 12/11/2025

Full Release

BRISBANE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on June 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 28,800 shares of Class A common stock and restricted stock units (RSUs) underlying 14,150 shares of Class A common stock to ten (10) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option granted on June 2, 2026 has an exercise price per share equal to $31.26, Vera Therapeutics’ closing trading price on June 2, 2026. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. Each of the RSU awards will vest over four years, with 25% of the underlying shares vesting on each anniversary of either May 20 or August 20, 2026, depending on the start date of the new employee, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.

About Vera Therapeutics
Vera Therapeutics is a biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics’ mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics’ lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN) and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell-mediated diseases. Vera Therapeutics is also evaluating development of MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109 and MAU868. For more information, please visit www.veratx.com .

For more information, please contact:

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
[email protected]

Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
[email protected]